Nutriband Inc. (NTRB)
| Market Cap | 77.19M -24.5% |
| Revenue (ttm) | 1.62M -37.3% |
| Net Income | -6.96M |
| EPS | -0.57 |
| Shares Out | 12.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,009 |
| Open | 6.10 |
| Previous Close | 6.65 |
| Day's Range | 6.10 - 6.10 |
| 52-Week Range | 2.80 - 9.19 |
| Beta | 1.93 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 4, 2026 |
About NTRB
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Financial Performance
In fiscal year 2026, Nutriband's revenue was $2.04 million, a decrease of -4.81% compared to the previous year's $2.14 million. Losses were -$30.04 million, 186.6% more than in 2025.
Financial StatementsNews
Nutriband files non-provisional utility Aversa patent application with USPTO
Nutriband (NTRB) announced that it has filed a non-provisional utility patent application with the U.S. Patent and Trademark Office, or USPTO, to further strengthen Nutriband’s intellectual property p...
Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology
Nutriband files new non-provisional patent application to strengthen intellectual property protection of its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opio...
Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
Nutriband CEO Gareth Sheridan Congratulates Shareholders on Five-Year Nasdaq Listing Anniversary CEO letter reflects on five years of milestones since the Company's October 1, 2021 uplisting, as AVERS...
Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis
ORLANDO, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that its CEO, Gareth Sheridan, has been featured in a new documentary by independent journa...
Nutriband appoints O’Neill to Advisory Board
Nutriband (NTRB) announced the appointment of Robert O’Neill to its Advisory Board. O’Neill is a former U.S. Navy SEAL, New York Times best-selling author, and speaker on leadership and resilience.
Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
ORLANDO, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) confirmed today that its outstanding warrants (NASDAQ:NTRBW) will expire on September 30, 2026 at 5PM ET a...
Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
ORLANDO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO, Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on Septe...
Nutriband receives notice of publication from USPTO
Nutriband (NTRB) announced that it has received a notice of publication from the United States Patent and Trademark Office, or USPTO, for commercial brand name trademarks for its lead product,…
Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch
Nutriband has received a Notice of Publication from the United States Patent and Trademark Office (USPTO) for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transde...
Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
ORLANDO, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan will present at the 2026 Georgia Life Sciences...
Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
Nutriband's Active Intelligence subsidiary to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference Company to Meet with Buyers from Walmart Inc, Walgreens,...
Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
ORLANDO, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan has featured on the latest episode of the Jac...
Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Nutriband has selected the commercial worldwide brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit to the FDA for approval per FDA Guidance. Nutriband par...
Nutriband’s Kinesiology Tapes approved for distribution and sale in Costa Rica
Nutriband (NTRB) announced that The Costa Rica Ministry of Health has approved the Company’s line of Kinesiology Tapes for import and Sale. Innomedica CCB, the company’s exclusive distribution partner...
Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica
ORLANDO, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that it has signed an exclusive distribution agreement with Costa Rica Based Innomedica f...
Nutriband signs exclusive distribution agreement with Innomedica
Nutriband (NTRB) signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports tape products manufactured at its Pocono Pharmaceutical / ...
Nutriband provides summary of annual shareholder meeting
Nutriband (NTRB) has provided an update to shareholders on the key milestones and discussions from this years Annual Shareholders Meeting. Addition of Two New Directors: Allesandro Puddu and Viorica C...
Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points
ORLANDO, Fla., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) has provided an update to shareholders on the key milestones and discussions from this years Annual Share...
Nutriband says ‘committed’ to shareholder value as ‘number one focus’
Nutriband (NTRB) announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2025 and the potential outlook for 2026. The letter...
Nutriband CEO Publishes Letter to Shareholders
ORLANDO, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achie...
Nutriband to sell majority stake of Pocono Pharmaceutical for $5M
Nutriband (NTRB) signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical for $5M to EarthVision Bio. Nutriband. Shareholders will retain 10% of the shareholding in Earth…
Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
Earthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke, ex-chairman for Chevron Europe N...
Nutriband signs LOI with Qvanta Group of companies
Nutriband (NTRB) announced the signing of a non-binding Letter of Intent with the Qvanta Group of Companies. The Qvanta Group comprises Qvanta and its subsidiaries, Qvanta Foundry and Qvanta Capital.
Nutriband provides response to Trump’s Executive Order related to fentanyl
Nutriband (NTRB) provides the following response to the Trump Administration’s Executive Order designating illicit fentanyl and its core precursor chemicals as weapons of mass destruction. “The design...
Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
Prescription pharmaceutical transdermal fentanyl is a valuable treatment for management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatmen...